Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Recurrence 1Primary Myelofibrosis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 25Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × INCB057643 × Clear all
NCT04279847 2026-04-01

LIMBER

Incyte Corporation

Phase 1 Active not recruiting
140 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡